Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

AC Immune (ACIU) Return on Sales (2016 - 2026)

AC Immune has reported Return on Sales over the past 9 years, most recently at 0.13% for Q1 2026.

  • Quarterly Return on Sales rose 6.0% to 0.13% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.18% through Mar 2026, down 16.0% year-over-year, with the annual reading at 0.2% for FY2025, 18.0% down from the prior year.
  • Return on Sales was 0.13% for Q1 2026 at AC Immune, up from 0.43% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.0% in Q3 2024 and troughed at 0.43% in Q4 2025.
  • The 4-year median for Return on Sales is 0.16% (2025), against an average of 0.18%.
  • The largest YoY upside for Return on Sales was 17bps in 2025 against a maximum downside of -29bps in 2025.
  • A 4-year view of Return on Sales shows it stood at 0.03% in 2022, then tumbled by -301bps to 0.14% in 2024, then plummeted by -206bps to 0.43% in 2025, then skyrocketed by 69bps to 0.13% in 2026.
  • Per Business Quant, the three most recent readings for ACIU's Return on Sales are 0.13% (Q1 2026), 0.43% (Q4 2025), and 0.17% (Q3 2025).